Apr 1, 2016EMA launched PRIME..
This voluntary scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimise development plans and speed up evaluation so these medicines can reach patients earlier.
Through PRIME, the Agency offers early and proactive support to medicine developers to optimise the generation of robust data on a medicines benefits and risks and enable accelerated assessment of medicines applications.
This will help patients to benefit as early as possible from therapies that may significantly improve their quality of life.
Go to: EMA PRIME